Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155
A. Lepletier de Oliveira(QIMR Berghofer Medical Research Institute), Mark J. Smyth(Peter MacCallum Cancer Centre), Michele W.L. Teng(The University of Queensland), Mario Mandalà(University of Perugia), Melissa Eastgate(The University of Queensland), Daniela Massi(University of Florence), Tobias Bald(QIMR Berghofer Medical Research Institute), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jason Madore(QIMR Berghofer Medical Research Institute), Barbara Merelli(Ospedale Papa Giovanni XXIII), Bertrand Routy(Centre Hospitalier de l’Université de Montréal), William C. Dougall(Queensland University of Technology), Domenico Mallardo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jake S. O’Donnell(The University of Queensland), Georgina V. Long(The University of Sydney), Rebecca L. Johnston(QIMR Berghofer Medical Research Institute), Richard A. Scolyer(The University of Sydney), James S. Wilmott(The University of Sydney), J. C. A. Stagg(QIMR Berghofer Medical Research Institute), Nicola Waddell(QIMR Berghofer Medical Research Institute)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k